Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
August 12, 2021 17:15 ET
|
Processa Pharmaceuticals, Inc.
Adds fourth clinical asset, RX-3117, and targets major milestones in the second half of 2021 HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a...
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
June 17, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP)...